News Column

New Immunotherapy Findings from V.M. Subbotin et al Outlined (Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical...

August 22, 2014



New Immunotherapy Findings from V.M. Subbotin et al Outlined (Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical solution)

By a News Reporter-Staff News Editor at Drug Week -- Current study results on Biotechnology have been published. According to news originating from Madison, Wisconsin, by NewsRx editors, the research stated, "Anticancer dendritic cells (DC) therapy currently uses in vitro propagation of the patient's DC and pulsing with tumor antigens. However, clinical achievements are far from desirable."

Our news journalists obtained a quote from the research, "Here, I suggest that the lack of anticipated responses could be because cancer cells continuously mutate, whereas the population of tumor antigens from the excised tumor is genetically static, and because there is an absence of biologic mechanisms to facilitate intratumoral DC retention, which is needed for DC pulsing. I hypothesize that stable tumor transfection with fetal liver tyrosine kinase 3 ligand (Flt3-L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) DNAs will induce homing, propagation and maturation of intratumoral DC. This must be followed by drug-induced apoptosis of tumor cells, to ensure the release of tumor antigens for DC pulsing."

According to the news editors, the research concluded: "Then, regardless of any mutation of tumor cells, they would always incite DC propagation and maturation, pulsing and antitumor immunity."

For more information on this research see: Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical solution. Drug Discovery Today, 2014;19(7):834-837. Drug Discovery Today can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Drug Discovery Today - www.elsevier.com/wps/product/cws_home/30921)

The news correspondents report that additional information may be obtained from V.M. Subbotin, 602 Samuel Dr, Madison, WI 53717, United States (see also Biotechnology).

Keywords for this news article include: Antigen-Presenting Cells, Biotechnology, Cancer, Madison, Genetics, Oncology, Wisconsin, Immunology, United States, Immunotherapy, Dendritic Cells, Immunomodulation, Biological Factors, North and Central America, Mononuclear Phagocyte System

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters